Aberdeen Group plc Raises Holdings in Vaxcyte, Inc. $PCVX

Key Points

• Aberdeen Group plc increased its holdings in Vaxcyte, Inc. by 17.8%, owning approximately 0.21% of the company, worth nearly $10 million as of the end of the first quarter.
• Vaxcyte reported a quarterly loss per share of ($1.22), missing analyst estimates, with expectations of a projected loss of ($4.21) EPS for the current fiscal year.
• Analysts generally rate Vaxcyte as a "Buy", with a consensus price target of $136.50, indicating significant potential upside.

Aberdeen Group plc grew its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 17.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 264,737 shares of the company's stock after acquiring an additional 39,913 shares during the quarter. Aberdeen Group plc owned about 0.21% of Vaxcyte worth $9,996,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. Parallel Advisors LLC raised its position in Vaxcyte by 203.6% in the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock worth $61,000 after buying an additional 1,071 shares during the last quarter. IFP Advisors Inc raised its stake in shares of Vaxcyte by 376.4% in the first quarter. IFP Advisors Inc now owns 1,653 shares of the company's stock worth $62,000 after buying an additional 1,306 shares during the period. Nisa Investment Advisors LLC raised its stake in Vaxcyte by 10.9% during the 1st quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock worth $112,000 after acquiring an additional 293 shares during the period. J.Safra Asset Management Corp lifted its stake in shares of Vaxcyte by 65.8% during the 1st quarter. J.Safra Asset Management Corp now owns 3,161 shares of the company's stock valued at $119,000 after buying an additional 1,254 shares in the last quarter. Finally, GF Fund Management CO. LTD. raised its holdings in Vaxcyte by 22.0% during the first quarter. GF Fund Management CO. LTD. now owns 3,192 shares of the company's stock valued at $121,000 after acquiring an additional 575 shares during the period. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Cowen reissued a "buy" rating on shares of Vaxcyte in a report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the stock. According to MarketBeat.com, Vaxcyte has an average rating of "Buy" and a consensus target price of $136.50.

Vaxcyte Stock Down 5.7%

Shares of NASDAQ PCVX traded down $1.84 during midday trading on Monday, reaching $30.45. 1,866,803 shares of the company's stock traded hands, compared to its average volume of 1,390,795. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06. The stock's 50 day simple moving average is $33.56 and its 200-day simple moving average is $43.70. The company has a market cap of $3.95 billion, a price-to-earnings ratio of -7.41 and a beta of 1.21.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period in the previous year, the company earned ($1.10) earnings per share. Equities analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.